Literature DB >> 10160111

Current principles and application of pharmacoeconomics.

M Malek1.   

Abstract

Anti-infective drugs account for between 3 and 25% of all prescriptions, between 6 and 21% of the total market value of drugs in a single country, and up to 50% of the drug budget in hospitals. Not surprisingly, in an era when cost-containment policies are at the top of the agenda, issues related to pharmaco-economics of antibacterial treatment have assumed an important part in these policies. However, there are still some misunderstandings regarding the precise terminology and difference in methodology of pharmacoeconomics. The aim of this paper is to explain the genealogy of pharmacoeconomics and various methods currently used in the application of this young discipline to anti-infective treatment.

Mesh:

Substances:

Year:  1996        PMID: 10160111     DOI: 10.2165/00019053-199600091-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  8 in total

1.  A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals.

Authors:  M Malek; W Lynch; N Wells; T Elliott; A Bint; P Sanderson; M Jaderberg; P Davey
Journal:  J Antimicrob Chemother       Date:  1992-02       Impact factor: 5.790

2.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

3.  Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.

Authors:  K A Freedberg; A N Tosteson; C J Cohen; D J Cotton
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

4.  Cost-effectiveness analysis of the use of chlorhexidine detergent in preoperative whole-body disinfection in wound infection prophylaxis.

Authors:  W Lynch; P G Davey; M Malek; D J Byrne; A Napier
Journal:  J Hosp Infect       Date:  1992-07       Impact factor: 3.926

5.  Cost-effectiveness of single dose cefotaxime plus metronidazole compared with three doses each of cefuroxime plus metronidazole for the prevention of wound infection after colorectal surgery.

Authors:  P Davey; B Lynch; M Malek; D Byrne; P Thomas
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

6.  Outpatient use of ceftriaxone: a cost-benefit analysis.

Authors:  D M Poretz; D Woolard; L J Eron; R I Goldenberg; J Rising; S Sparks
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

Review 7.  Cost-effectiveness of primary tetanus vaccination among elderly Canadians.

Authors:  B G Hutchison; G L Stoddart
Journal:  CMAJ       Date:  1988-12-15       Impact factor: 8.262

8.  Benefit-cost analysis of antimicrobial prophylaxis in abdominal and vaginal hysterectomy.

Authors:  M Shapiro; S C Schoenbaum; I B Tager; A Muñoz; B F Polk
Journal:  JAMA       Date:  1983-03-11       Impact factor: 56.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.